Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Pharmacy, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China.
Front Immunol. 2022 Aug 12;13:932938. doi: 10.3389/fimmu.2022.932938. eCollection 2022.
Emerging evidence shows immune-related long noncoding RNAs (ir-lncRNAs) perform critical roles in tumor progression and prognosis assessment. However, the identification of ir-lncRNAs and their clinical significance in human glioblastoma multiforme (GBM) remain largely unexplored. Here, a designed computational frame based on immune score was used to identify differentially expressed ir-lncRNAs (DEir-lncRNAs) from The Cancer Genome Atlas (TCGA) GBM program. The immune-related lncRNA signature (IRLncSig) composed of prognosis-related DEir-lncRNAs selected by Cox regression analysis and its clinical predictive values were verified, which was further validated by another dataset from the Gene Expression Omnibus database (GEO). Subsequently, the association between IRLncSig and immune cell infiltration, immune checkpoint inhibitor (ICI) biomarkers, O6-methylguanine-DNA methyltransferase (MGMT) gene expression, and biological function were also analyzed. After calculation, five prognosis-related ir-lncRNAs were included in the establishment of IRLncSig. The risk assessment based on IRLncSig indicated that the high-IRLncSig-score group was significantly associated with poor prognosis ( < 0.001), significant aggregation of macrophages ( < 0.05), higher ICI biomarker expression, and MGMT gene expression ( < 0.05). Signature-related lncRNAs may be involved in immune activities in the tumorigenesis and progression of GBM. In summary, the novel IRLncSig shows a promising clinical value in predicting the prognosis and immune landscape of GBM.
新出现的证据表明，免疫相关的长非编码 RNA（ir-lncRNA）在肿瘤进展和预后评估中发挥着关键作用。然而，ir-lncRNA 在人类胶质母细胞瘤（GBM）中的鉴定及其临床意义在很大程度上仍未得到探索。在这里，基于免疫评分设计了一个计算框架，用于从癌症基因组图谱（TCGA）GBM 计划中识别差异表达的 ir-lncRNA（DEir-lncRNA）。由 Cox 回归分析选择的与预后相关的 DEir-lncRNA 组成的免疫相关 lncRNA 特征（IRLncSig）及其临床预测价值得到了验证，并通过来自基因表达综合数据库（GEO）的另一个数据集进一步验证。随后，还分析了 IRLncSig 与免疫细胞浸润、免疫检查点抑制剂（ICI）生物标志物、O6-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）基因表达和生物学功能之间的关联。计算后，将五个与预后相关的 ir-lncRNA 纳入 IRLncSig 的建立。基于 IRLncSig 的风险评估表明，高 IRLncSig 评分组与预后不良显著相关（<0.001），巨噬细胞显著聚集（<0.05），ICI 生物标志物表达和 MGMT 基因表达更高（<0.05）。特征相关的 lncRNA 可能参与 GBM 发生和进展中的免疫活动。总之，新的 IRLncSig 在预测 GBM 的预后和免疫景观方面具有有前途的临床价值。
